Latest News and Press Releases

Highly experienced in gene therapy dealmaking, Pettenaro will be driving Coave’s business development activities and establish its presence in the Boston biotech hub  Paris, France, and Cambridge,...

Paris, France, April 9, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, announces that members of its leadership team will be attending the following...

Le tour de table a été mené par Novo Holdings A/S et Bpifrance (dans le cadre de la stratégie d'investissement InnoBio), avec la participation d'investisseurs américains et européens, Invus et UI...

Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US and EU investors Invus and UI Investissement alongside existing...

PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US    Symptoms often start in childhood leading to blindness by midlife with no approved...

Coave’s proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ligands at the surface of the capsid,...

Paris, France, September 24, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company pioneering therapies for eye and neurodegenerative diseases, will present the first data on its...

          Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month follow-up           Phase I/II results will be discussed with US and...

coAAV-mediated gene transfer holds promise for expanding the scope of ocular diseases treatable via suprachoroidal administration Data to be presented in oral session at ASGCT 2024 Paris,...

Paris, France, April 25, 2024 – eyeDNA Therapeutics (‘eyeDNA’), a newly created subsidiary of Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies,...